Chemoprevention, chemotherapy, and chemoresistance in colorectal cancer

Drug Metabolism Reviews

Volumn 44, Issue 2, 2012, Pages 148-172

  Marin, Jose J G ^a   Sanchez De Medina, Fermin ^b   Castão, Beatriz ^c   Bujanda, Luis ^d   Romero, Marta R ^a   Martinez Augustin, Olga ^b   Del Moral Avila, Rosario ^e   Briz, Oscar ^c  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

^c HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^d UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

Author keywords

Cancer; Drug; Metabolism; Pharmacology; Refractoriness; Sensitivity; Transport

Indexed keywords

7 HYDROXYSTAUROSPORINE; ACETYLSALICYLIC ACID; BEVACIZUMAB; BUTYRIC ACID; CALCIUM; CAPECITABINE; CEDIRANIB; CELECOXIB; CETUXIMAB; DASATINIB; EFLORNITHINE; ERLOTINIB; FLUOROURACIL; FOLIC ACID; HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRINOTECAN; MESALAZINE; OBLIMERSEN; OXALIPLATIN; PANITUMUMAB; PROSTAGLANDIN SYNTHASE INHIBITOR; SELENIUM; SEMAXANIB; STAUROSPORINE; SULINDAC; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; VATALANIB; VITAMIN D;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURGERY; CANCER SURVIVAL; CHEMOPROPHYLAXIS; COLORECTAL CANCER; EARLY CANCER; EARLY DIAGNOSIS; HUMAN; METASTASIS; MONOTHERAPY; RECURRENCE RISK; REVIEW; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOPREVENTION; COLORECTAL NEOPLASMS; CYCLOOXYGENASE INHIBITORS; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASM RECURRENCE, LOCAL; PRIMARY PREVENTION; SECONDARY PREVENTION;

EID: 84859698114     PISSN: 03602532     EISSN: 10979883     Source Type: Journal    
DOI: 10.3109/03602532.2011.638303     Document Type: Review

References (244)

1. Abdelnour-Berchtold, E., Cerantola, Y., Roulin, D., Dormond-Meuwly, A., Demartines, N., Dormond, O. (2010). Rapamycin-mediated FOXO1 inactivation reduces the anticancer efficacy of rapamycin. Anticancer Res 30:799-804.
2. Abe, T, Unno, M., Onogawa, T., Tokui, T., Kondo, T. N., Nakagomi, R., et al. (2001). LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology 120:1689-1699. (Pubitemid 32523487)
3. Abuli, A., Bessa, X., Gonzalez, J. R., Ruiz-Ponte, C., Caceres, A., Munoz, J., et al. (2010). Susceptibility genetic variants associated with colorectal cancer risk correlate with cancer phenotype. Gastroenterology 139:788-796.
4. Alberts, D. S., Martinez, M. E., Hess, L. M., Einspahr, J. G., Green, S. B., Bhattacharyya, A. K., et al. (2005). Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. J Natl Cancer Inst 97:846-853. (Pubitemid 40909127)
5. Alberts, D. S., Martinez, M. E., Roe, D. J., Guillen-Rodriguez, J. M., Marshall, J. R., van Leeuwen, J. B., et al. (2000). Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians' Network. N Engl J Med 342:1156-1162. (Pubitemid 30211046)
6. Allegra, C. J., Yothers, G., O'Connell, M. J., Sharif, S., Colangelo, L. H., Lopa, S. H., et al. (2009). Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol 27:3385-3390.
7. Andre, T, Boni, C, Mounedji-Boudiaf, L, Navarro, M, Tabernero, J, Hickish, T, et al. (2004). Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343-2351. (Pubitemid 38702845)
8. Andre, T., Boni, C., Navarro, M., Tabernero, J., Hickish, T., Topham, C., et al. (2009). Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27:3109-3116.
9. Andre, T, Colin, P, Louvet, C, Gamelin, E, Bouche, O, Achille, E, et al. (2003). Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol 21:2896-2903. (Pubitemid 46621839)
10. Andre, T., Louvet, C., Maindrault-Goebel, F., Couteau, C., Mabro, M., Lotz, J. P., et al. (1999). CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer, 35, 1343-7. (Pubitemid 29397434)
11. Andre, T., Quinaux, E., Louvet, C., Colin, P., Gamelin, E., Bouche, O., et al. (2007). Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1. J Clin Oncol 25:3732-3738. (Pubitemid 47372615)
12. Arango, D., Mariadason, J. M., Wilson, A. J., Yang, W., Corner, G. A., Nicholas, C., et al. (2003). c-Myc overexpression sensitises colon cancer cells to camptothecin-induced apoptosis. Br J Cancer 89:1757-1765. (Pubitemid 37464151)
13. Arango, D., Wilson, A. J., Shi, Q., Corner, G. A., Aranes, M. J., Nicholas, C., et al. (2004). Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br J Cancer 91:1931-1946. (Pubitemid 40065523)
14. Arnould, S., Hennebelle, I., Canal, P., Bugat, R., Guichard, S. (2003). Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines. Eur J Cancer 39:112-119. (Pubitemid 36005433)
15. Ashley, A. C., Sargent, D. J., Alberts, S. R., Grothey, A., Campbell, M. E., Morton, R. F., et al. (2007). Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX): intergroup trial N9741 in firstline treatment of metastatic colorectal cancer. Cancer 110:670-677. (Pubitemid 47106158)
16. Ballestero, M. R., Monte, M. J., Briz, O., Jimenez, F., Gonzalez-San Martin, F., Marin, J. J. (2006). Expression of transporters potentially involved in the targeting of cytostatic bile acid derivatives to colon cancer and polyps. Biochem Pharmacol 72:729-738. (Pubitemid 44233549)
17. Baron, J. A., Beach, M., Mandel, J. S., van Stolk, R. U., Haile, R. W., Sandler, R. S., et al. (1999). Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group. N Engl J Med 340:101-107. (Pubitemid 29054844)
18. Becerra, C. R., Frenkel, E. P., Ashfaq, R., Gaynor, R. B. (2003). Increased toxicity and lack of efficacy of rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: a phase II study. Int J Cancer 105:868-872. (Pubitemid 36706113)
19. Bennett, A., Del Tacca, M. (1975). Proceedings: prostaglandins in human colonic carcinoma. Gut 16:409.
20. Benson, A. B., 3rd, Schrag, D., Somerfield, M. R., Cohen, A. M., Figueredo, A. T., Flynn, P. J., et al. (2004). American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22:3408-3419. (Pubitemid 41103700)
21. Beresford, S. A., Johnson, K. C., Ritenbaugh, C., Lasser, N. L., Snetselaar, L. G., Black, H. R., et al. (2006). Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA 295:643-654. (Pubitemid 43209066)
22. Bertagnolli, M. M., Eagle, C. J., Zauber, A. G., Redston, M., Breazna, A., Kim, K., et al. (2009). Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila) 2:310-321.
23. Bingham, S. A., Day, N. E., Luben, R., Ferrari, P., Slimani, N., Norat, T., et al. (2003). Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): an observational study. Lancet 361:1496-1501. (Pubitemid 36566339)
24. Bonithon-Kopp, C., Kronborg, O., Giacosa, A., Rath, U., Faivre, J. (2000). Calcium and fibre supplementation in prevention of colorectal adenoma recurrence: a randomised intervention trial. European Cancer Prevention Organisation Study Group. Lancet 356:1300-1306.
25. Boonsong, A., Marsh, S., Rooney, P. H., Stevenson, D. A., Cassidy, J., McLeod, H. L. (2000). Characterization of the topoisomerase I locus in human colorectal cancer. Cancer Genet Cytogenet 121:56-60. (Pubitemid 30665742)
26. Briz, O., Macias, R. I., Vallejo, M., Silva, A., Serrano, M. A., Marin, J. J. (2003). Usefulness of liposomes loaded with cytostatic bile acid derivatives to circumvent chemotherapy resistance of enterohepatic tumors. Mol Pharmacol 63:742-750. (Pubitemid 36297348)
27. Budd, G. T., Fleming, T. R., Bukowski, R. M., McCracken, J. D., Rivkin, S. E., O'Bryan, R. M., et al. (1987). 5-Fluorouracil and folinic acid in the treatment of metastatic colorectal cancer: a randomized comparison. A Southwest Oncology Group Study. J Clin Oncol 5:272-277. (Pubitemid 17021611)
28. Bujanda, L., Sarasqueta, C., Hijona, E., Hijona, L., Cosme, A., Gil, I., et al. (2010). Colorectal cancer prognosis twenty years later. World J Gastroenterol 16:862-867.
29. Buyse, M., Zeleniuch-Jacquotte, A., Chalmers, T. C. (1988). Adjuvant therapy of colorectal cancer. Why we still don't know. JAMA 259:3571-3578.
30. Caponigro, F., Lacombe, D., Twelves, C., Bauer, J., Govaerts, A. S., Marreaud, S., et al. (2009). An EORTC phase I study of bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer. Eur J Cancer 45:48-55.
31. Carrato, A., Köhne, C., Bedenne, L., Popov, I., Bouche, O., Gaspar, E., et al. (2006). Folinic acid modulated bolus 5-FU or infusional 5-FU for adjuvant treatment of patients of UICC stage III colon cancer: preliminary analysis of the PETACC-2-study. 2006 ASCO Annual Meeting Proceedings J Clin Oncol 24:18S.
32. Cascinu, S., Berardi, R., Salvagni, S., Beretta, G. D., Catalano, V., Pucci, F., et al. (2008). A combination of gefitinib and FOLFOX-4 as firstline treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification, and NF-kB activation. Br J Cancer 98:71-76.
33. Cassidy, J, Clarke, S, Diaz-Rubio, E, Scheithauer, W, Figer, A, Wong, R, et al. (2008). Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 26:2006-2012.
34. Cassidy, J., Douillard, J. Y., Twelves, C., McKendrick, J. J., Scheithauer, W., Bustova, I., et al. (2006). Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial. Br J Cancer 94:1122-1129.
35. Cassidy, J., Tabernero, J., Twelves, C., Brunet, R., Butts, C., Conroy, T., et al. (2004). XELOX (capecitabine plus oxaliplatin): active firstline therapy for patients with metastatic colorectal cancer. J Clin Oncol 22:2084-2091. (Pubitemid 41095141)
36. Castells, A., Marzo-Castillejo, M., Mascort, J. J., Amador, F. J., Andreu, M., Bellas, B., et al. (2009). [Clinical practice guideline. Prevention of colorectal cancer. 2009 update. Asociacion Espanola de Gastroenterologia]. [Article in Spanish]. Gastroenterol Hepatol 32:717 e1-58.
37. Chan, A. T., Giovannucci, E. L. (2010). Primary prevention of colorectal cancer. Gastroenterology 138:2029-2043.
38. Chao, C. C., Huang, Y. T., Ma, C. M., Chou, W. Y., Lin-Chao, S. (1992). Overexpression of glutathione S-transferase and elevation of thiol pools in a multidrug-resistant human colon cancer cell line. Mol Pharmacol 41:69-75.
39. Chen, J., Huang, X. F., Katsifis, A. (2010). Activation of signal pathways and the resistance to anti-EGFR treatment in colorectal cancer. J Cell Biochem 111:1082-1086.
40. Chen, R., Nelson, J. A. (2000). Role of organic cation transporters in the renal secretion of nucleosides. Biochem Pharmacol 60:215-219. (Pubitemid 30312949)
41. Chibaudel, B., Maindrault-Goebel, F., Lledo, G., Mineur, L., Andre, T., Bennamoun, M., et al. (2009a). Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol 27:5727-5733.
42. Chibaudel, B., Tournigand, C., Artru, P., Andre, T., Cervantes, A., Figer, A., et al. (2009b). FOLFOX in patients with metastatic colorectal cancer and high alkaline phosphatase level: an exploratory cohort of the GERCOR OPTIMOX1 Study. Ann Oncol 20:1383-1386.
43. Chlebowski, R. T., Wactawski-Wende, J., Ritenbaugh, C., Hubbell, F. A., Ascensao, J., Rodabough, R. J., et al. (2004). Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 350:991-1004. (Pubitemid 38269276)
44. Cho, E., Smith-Warner, S. A., Spiegelman, D., Beeson, W. L., van den Brandt, P. A., Colditz, G. A., et al. (2004). Dairy foods, calcium, and colorectal cancer: a pooled analysis of 10 cohort studies. J Natl Cancer Inst 96:1015-1022. (Pubitemid 39162644)
45. Chu, E., Koeller, D. M., Johnston, P. G., Zinn, S., Allegra, C. J. (1993). Regulation of thymidylate synthase in human colon cancer cells treated with 5-fluorouracil and interferon-gamma. Mol Pharmacol 43:527-533. (Pubitemid 23112729)
46. Ciardiello, F., Tortora, G. (2001). A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 7:2958-2970. (Pubitemid 32963812)
47. Cohen, A. M. (1991). Surgical considerations in patients with cancer of the colon and rectum. Semin Oncol 18:381-387.
48. Cole, B. F., Baron, J. A., Sandler, R. S., Haile, R. W., Ahnen, D. J., Bresalier, R. S., et al. (2007). Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA 297:2351-2359. (Pubitemid 46883748)
49. Comella, P., Palmieri, G., Lorusso, V., Catalano, G., Nicollela, D., Ianniello, G. P., et al. (1996). Double biochemical modulation of 5-fluorouracil by methotrexate and levo-folinic acid in the treatment of advanced digestive tract malignancies. Eur J Cancer 32A:1719-1726. (Pubitemid 26306883)
50. Compton, C. C., Fielding, L. P., Burgart, L. J., Conley, B., Cooper, H. S., Hamilton, S. R., et al. (2000). Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124:979-994.
51. Compton, C. C., Greene, F. L. (2004). The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin 54:295-308. (Pubitemid 40073988)
52. Cook, N. R., Lee, I. M., Gaziano, J. M., Gordon, D., Ridker, P. M., Manson, J. E., et al. (2005). Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 294:47-55. (Pubitemid 41002838)
53. Cummings, J., Ethell, B. T., Jardine, L., Boyd, G., Macpherson, J. S., Burchell, B., et al. (2003). Glucuronidation as a mechanism of intrinsic drug resistance in human colon cancer: reversal of resistance by food additives. Cancer Res 63:8443-8450. (Pubitemid 37553155)
54. Cunningham, D. (1998). Mature results from three large controlled studies with raltitrexed ('Tomudex'). Br J Cancer 77:15-21.
55. Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., et al. (2004). Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345. (Pubitemid 38944402)
56. Cuzick, J., Otto, F., Baron, J. A., Brown, P. H., Burn, J., Greenwald, P., et al. (2009). Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 10:501-507.
57. Dart, D. A., Picksley, S. M., Cooper, P. A., Double, J. A., Bibby, M. C. (2004). The role of p53 in the chemotherapeutic responses to cisplatin, doxorubicin and 5-fluorouracil treatment. Int J Oncol 24: 115-125.
58. de Gramont, A., Bosset, J. F., Milan, C., Rougier, P., Bouche, O., Etienne, P. L., et al. (1997). Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly highdose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 15:808-815. (Pubitemid 27074252)
59. de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., et al. (2000). Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947. (Pubitemid 30644117)
60. Dencausse, Y., Hartung, G., Sturm, J., Kopp-Schneider, A., Hagmuller, E., Wojatschek, C., et al. (2002). Adjuvant chemotherapy in stage III colon cancer with 5-fluorouracil and levamisole versus 5-fluorouracil and leucovorin. Onkologie 25:426-430. (Pubitemid 36160181)
61. Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., et al. (2008). Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26:5705-5712.
62. Donada, M., Bonin, S., Nardon, E., De Pellegrin, A., Decorti, G., Stanta, G. (2011). Thymidilate synthase expression predicts longer survival in patients with stage II colon cancer treated with 5-flurouracil independently of microsatellite instability. J Cancer Res Clin Oncol 137:201-210.
63. Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., et al. (1998). Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279:1615-1622. (Pubitemid 28248586)
64. DuBois, R. N., Radhika, A., Reddy, B. S., Entingh, A. J. (1996). Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology 110:1259-1262. (Pubitemid 26113767)
65. Dudkin, L., Dilling, M. B., Cheshire, P. J., Harwood, F. C., Hollingshead, M., Arbuck, S. G., et al. (2001). Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res 7:1758-1764. (Pubitemid 32708646)
66. Dunn, E. F., Iida, M., Myers, R. A., Campbell, D. A., Hintz, K. A., Armstrong, E. A., et al. (2011). Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab. Oncogene 30:561-574.
67. Efferth, T., Konkimalla, V. B., Wang, Y. F., Sauerbrey, A., Meinhardt, S., Zintl, F., et al. (2008). Prediction of broad spectrum resistance of tumors towards anticancer drugs. Clin Cancer Res 14:2405-2412. (Pubitemid 351551074)
68. El-Rayes, B. F., Zalupski, M. M., Manza, S. G., Rusin, B., Ferris, A. M., Vaishampayan, U., et al. (2008). Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer. Cancer Chemother Pharmacol 61:283-289. (Pubitemid 350160326)
69. Elias, D., Benizri, E., Di Pietrantonio, D., Menegon, P., Malka, D., Raynard, B. (2007). Comparison of two kinds of intraperitoneal chemotherapy following complete cytoreductive surgery of colorectal peritoneal carcinomatosis. Ann Surg Oncol 14:509-514. (Pubitemid 46175295)
70. Elit, L. (2002). CCI-779 Wyeth. Curr Opin Investig Drugs 3:1249-1253.
71. Endo, K., Kohnoe, S., Watanabe, A., Tashiro, H., Sakata, H., Morita, M., et al. (2009). Clinical significance of Smac/DIABLO expression in colorectal cancer. Oncol Rep 21:351-355.
72. Endo, Y., Obata, T., Murata, D., Ito, M., Sakamoto, K., Fukushima, M., et al. (2007). Cellular localization and functional characterization of the equilibrative nucleoside transporters of antitumor nucleosides. Cancer Sci 98:1633-1637. (Pubitemid 47308462)
73. Etienne, M. C., Chazal, M., Laurent-Puig, P., Magne, N., Rosty, C., Formento, J. L., et al. (2002). Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses. J Clin Oncol 20:2832-2843. (Pubitemid 34651512)
74. Fakih, M. G., Pendyala, L., Fetterly, G., Toth, K., Zwiebel, J. A., Espinoza-Delgado, I., et al. (2009). A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer. Clin Cancer Res 15:3189-3195.
75. Falcone, A, Ricci, S, Brunetti, I, Pfanner, E, Allegrini, G, Barbara, C, et al. (2007). Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 25:1670-1676. (Pubitemid 46797946)
76. Ferlay, J., Shin, H. R., Bray, F., Forman, D., Mathers, C., Parkin, D. M. (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893-2917.
77. Fink, D., Aebi, S., Howell, S. B. (1998). The role of DNA mismatch repair in drug resistance. Clin Cancer Res 4:1-6. (Pubitemid 28062870)
78. Folprecht, G., Lutz, M. P., Schoffski, P., Seufferlein, T., Nolting, A., Pollert, P., et al. (2006). Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 17:450-456. (Pubitemid 43329582)
79. Folprecht, G., Tabernero, J., Kohne, C. H., Zacharchuk, C., Paz-Ares, L., Rojo, F., et al. (2008). Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with metastatic colorectal cancer. Clin Cancer Res 14:215-223. (Pubitemid 351377998)
80. Fong, T. A., Shawver, L. K., Sun, L., Tang, C., App, H., Powell, T. J., et al. (1999). SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 59:99-106. (Pubitemid 29062964)
81. Fuchs, C. S., Marshall, J., Mitchell, E., Wierzbicki, R., Ganju, V., Jeffery, M., et al. (2007). Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 25:4779-4786. (Pubitemid 350086481)
82. Fulda, S. (2009). Inhibitor of apoptosis (IAP) proteins: novel insights into the cancer-relevant targets for cell death induction. ACS Chem Biol 4:499-501.
83. Gallagher, DJ, Kemeny, N. (2010). Metastatic colorectal cancer: from improved survival to potential cure. Oncology 78:237-248.
84. Gann, P. H., Manson, J. E., Glynn, R. J., Buring, J. E., Hennekens, C. H. (1993). Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst 85:1220-1224. (Pubitemid 23223527)
85. Garland C. F., Garland, F. C., Gorham, E. D. (1999). Calcium and vitamin D. Their potential roles in colon and breast cancer prevention. Ann N Y Acad Sci 889, 107-119. (Pubitemid 30040430)
86. Giardiello, F. M., Hamilton, S. R., Hylind, L. M., Yang, V. W., Tamez, P., Casero, R. A., Jr. (1997). Ornithine decarboxylase and polyamines in familial adenomatous polyposis. Cancer Res 57:199-201. (Pubitemid 27036592)
87. Giardiello, F. M., Hamilton, S. R., Krush, A. J., Piantadosi, S., Hylind, L. M., Celano, P., et al. (1993). Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328:1313-1316. (Pubitemid 23131373)
88. Gill, S., Loprinzi, C. L., Sargent, D. J., Thome, S. D., Alberts, S. R., Haller, D. G., et al. (2004). Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 22:1797-1806. (Pubitemid 41095169)
89. Goldberg, R. M., Sargent, D. J., Morton, R. F., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., et al. (2004). A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30. (Pubitemid 41095110)
90. Gourdier, I., Del Rio, M., Crabbe, L., Candeil, L., Copois, V., Ychou, M., et al. (2002). Drug specific resistance to oxaliplatin is associated with apoptosis defect in a cellular model of colon carcinoma. FEBS Lett 529:232-236.
91. Gradilone, A., Pulcinelli, F. M., Lotti, L. V., Trifiro, E., Martino, S., Gandini, O., et al. (2008). Celecoxib upregulates multidrug resistance proteins in colon cancer: lack of synergy with standard chemotherapy. Curr Cancer Drug Targets 8:414-420.
92. Haller, D. G., Catalano, P. J., Macdonald, J. S., O'Rourke, M. A., Frontiera, M. S., Jackson, D. V., et al. (2005). Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol 23:8671-8678. (Pubitemid 46211510)
93. Haller, D. G., Tabernero, J., Maroun, J., de Braud, F., Price, T., Van Cutsem, E., et al. (2011). Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 29:1465-1471.
94. Hayward, R. L., Macpherson, J. S., Cummings, J., Monia, B. P., Smyth, J. F., Jodrell, D. I. (2004). Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent: genetic evidence for specificity of the antisense effect. Mol Cancer Ther 3:169-178. (Pubitemid 39193691)
95. Hecht, J. R., Patnaik, A., Berlin, J., Venook, A., Malik, I., Tchekmedyian, S., et al. (2007). Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer 110:980-988. (Pubitemid 47312862)
96. Hinoshita, E., Uchiumi, T., Taguchi, K., Kinukawa, N., Tsuneyoshi, M., Maehara, Y., et al. (2000). Increased expression of an ATPbinding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomas. Clin Cancer Res 6: 2401-2407. (Pubitemid 30399208)
97. Hishikawa, Y., Kohno, H., Ueda, S., Kimoto, T., Dhar, D. K., Kubota, H., et al. (2001). Expression of metallothionein in colorectal cancers and synchronous liver metastases. Oncology 61:162-167. (Pubitemid 32786211)
98. Hixson, L. J., Garewal, H. S., McGee, D. L., Sloan, D., Fennerty, M. B., Sampliner, R. E., et al. (1993). Ornithine decarboxylase and polyamines in colorectal neoplasia and mucosa. Cancer Epidemiol Biomarkers Prev 2:369-374.
99. Hoff, P. M., Ansari, R., Batist, G., Cox, J., Kocha, W., Kuperminc, M., et al. (2001). Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19:2282-2292. (Pubitemid 32366981)
100. Holzer, A. K., Manorek, G. H., Howell, S. B. (2006a). Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. Mol Pharmacol 70:1390-1394. (Pubitemid 44435991)
101. Holzer, A. K., Varki, N. M., Le, Q. T., Gibson, M. A., Naredi, P., Howell, S. B. (2006b). Expression of the human copper influx transporter 1 in normal and malignant human tissues. J Histochem Cytochem 54:1041-1049. (Pubitemid 44298591)
102. Honjo, Y., Hrycyna, C. A., Yan, Q. W., Medina-Perez, W. Y., Robey, R. W., van de Laar, A., et al. (2001). Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCPoverexpressing cells. Cancer Res 61:6635-6639. (Pubitemid 32896477)
103. Huang, Y., Sadee, W. (2006). Membrane transporters and channels in chemoresistance and-sensitivity of tumor cells. Cancer Lett 239:168-182. (Pubitemid 43996825)
104. Huerta, S., Heinzerling, J. H., Anguiano-Hernandez, Y. M., Huerta-Yepez, S., Lin, J., Chen, D., et al. (2007). Modification of gene products involved in resistance to apoptosis in metastatic colon cancer cells: roles of Fas, Apaf-1, NFkappaB, IAPs, Smac/DIABLO, and AIF. J Surg Res 142:184-194. (Pubitemid 47277413)
105. Hurwitz, H, Fehrenbacher, L, Novotny, W, Cartwright, T, Hainsworth, J, Heim, W, et al. (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342. (Pubitemid 38702844)
106. Itzkowitz, S. H., Harpaz, N. (2004). Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology 126:1634-1648. (Pubitemid 38649879)
107. Izquierdo, M. A., Scheffer, G. L., Flens, M. J., Giaccone, G., Broxterman, H. J., Meijer, C. J., et al. (1996). Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors. Am J Pathol 148:877-887. (Pubitemid 126660679)
108. Jackson, N. A., Barrueco, J., Soufi-Mahjoubi, R., Marshall, J., Mitchell, E., Zhang, X., et al. (2009). Comparing safety and efficacy of firstline irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostarcelecoxib study. Cancer 115:2617-2629.
109. Jacobs, E. T., Jiang, R., Alberts, D. S., Greenberg, E. R., Gunter, E. W., Karagas, M. R., et al. (2004). Selenium and colorectal adenoma: results of a pooled analysis. J Natl Cancer Inst 96:1669-1675. (Pubitemid 39591588)
110. Jaffe, B. M. (1974). Prostaglandins and cancer: an update. Prostaglandins 6:453-461.
111. Jenab, M., Bueno-de-Mesquita, H. B., Ferrari, P., van Duijnhoven, F. J., Norat, T., Pischon, T., et al. (2010). Association between pre-diagnostic circulating vitamin D concentration and risk of colorectal cancer in European populations:a nested case-control study. BMJ 340:b5500.
112. Jimeno, A., Gravalos, C., Escudero, P., Sevilla, I., Vega-Villegas, M. E., Alonso, V., et al. (2008). Phase I/II study of gefitinib and capecitabine in patients with colorectal cancer. Clin Transl Oncol 10:52-57.
113. Johnston, P. G., Lenz, H. J., Leichman, C. G., Danenberg, K. D., Allegra, C. J., Danenberg, P. V., et al. (1995). Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55:1407-1412.
114. Jover, R., Zapater, P., Castells, A., Llor, X., Andreu, M., Cubiella, J., et al. (2009). The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. Eur J Cancer 45:365-373.
115. Kachnic, L. A. (2006). Should preoperative or postoperative therapy be administered in the management of rectal cancer? Semin Oncol 33:S64-S69.
116. Kaiser, S., Park, Y. K., Franklin, J. L., Halberg, R. B., Yu, M., Jessen, W. J., et al. (2007). Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer. Genome Biol 8:R131.
117. Kim, Y. I. (2003). Role of folate in colon cancer development and progression. J Nutr 133:3731S-3739S.
118. Kitazono, M., Sumizawa, T., Takebayashi, Y., Chen, Z. S., Furukawa, T., Nagayama, S., et al. (1999). Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells. J Natl Cancer Inst 91:1647-1653. (Pubitemid 29479932)
119. Kortmansky, J., Shah, M. A., Kaubisch, A., Weyerbacher, A., Yi, S., Tong, W., et al. (2005). Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors. J Clin Oncol 23:1875-1884. (Pubitemid 46211365)
120. Kozuch, P., Malamud, S., Wasserman, C., Homel, P., Mirzoyev, T., Grossbard, M. (2009). Phase II trial of erlotinib and capecitabine for patients with previously untreated metastatic colorectal cancer. Clin Colorectal Cancer 8:38-42.
121. Kuebler, J. P., Wieand, H. S., O'Connell, M. J., Smith, R. E., Colangelo, L. H., Yothers, G., et al. (2007). Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 25:2198-2204. (Pubitemid 46954643)
122. Kuo, M. T., Bao, J. J., Curley, S. A., Ikeguchi, M., Johnston, D. A., Ishikawa, T. (1996). Frequent coordinated overexpression of the MRP/GS-X pump and gamma-glutamylcysteine synthetase genes in human colorectal cancers. Cancer Res 56:3642-3644. (Pubitemid 26272004)
123. Kusuhara, H., Sugiyama, Y. (2007). ATP-binding cassette, subfamily G (ABCG family). Pflugers Arch 453:735-744. (Pubitemid 46192543)
124. Lacy, A. M., Garcia-Valdecasas, J. C., Delgado, S., Castells, A., Taura, P., Pique, J. M., et al. (2002). Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial. Lancet 359:2224-2229. (Pubitemid 34717975)
125. Laheru, D., Croghan, G., Bukowski, R., Rudek, M., Messersmith, W., Erlichman, C., et al. (2008). A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer. Clin Cancer Res 14:5602-5609.
126. Lashner, B. A., Provencher, K. S., Seidner, D. L., Knesebeck, A., Brzezinski, A. (1997). The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. Gastroenterology 112:29-32. (Pubitemid 27008982)
127. Lazaris, A. C., Kavantzas, N. G., Zorzos, H. S., Tsavaris, N. V., Davaris, P. S. (2002). Markers of drug resistance in relapsing colon cancer. J Cancer Res Clin Oncol 128:114-118.
128. Lee, J. H., Soung, Y. H., Lee, J. W., Park, W. S., Kim, S. Y., Cho, Y. G., et al. (2004). Inactivating mutation of the pro-apoptotic gene BID in gastric cancer. J Pathol 202:439-445. (Pubitemid 38456162)
129. Lembersky, BC, Wieand, HS, Petrelli, NJ, O'Connell, MJ, Colangelo, LH, Smith, RE, et al. (2006). Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 24:2059-2064. (Pubitemid 46622115)
130. Li, X. G., Haluska, P., Jr., Hsiang, Y. H., Bharti, A., Kufe, D. W., Rubin, E. H. (1996). Identification of topoisomerase I mutations affecting both DNA cleavage and interaction with camptothecin. Ann N Y Acad Sci 803:111-127. (Pubitemid 27057979)
131. Lin, X., Kim, H. K., Howell, S. B. (1999). The role of DNA mismatch repair in cisplatin mutagenicity. J Inorg Biochem 77:89-93. (Pubitemid 30089087)
132. Lockhart, AC, Cropp, GF, Berlin, JD, Donnelly, E, Schumaker, RD, Schaaf, LJ, et al. (2006). Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer. Am J Clin Oncol 29:109-115. (Pubitemid 44270946)
133. Logan, R. F., Grainge, M. J., Shepherd, V. C., Armitage, N. C., Muir, K. R. (2008). Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology 134:29-38. (Pubitemid 350309319)
134. Longley, D. B., Wilson, T. R., McEwan, M., Allen, W. L., McDermott, U., Galligan, L., et al. (2006). c-FLIP inhibits chemotherapy-induced colorectal cancer cell death. Oncogene 25:838-848. (Pubitemid 43237702)
135. Love, R. R., Jacoby, R., Newton, M. A., Tutsch, K. D., Simon, K., Pomplun, M., et al. (1998). A randomized, placebo-controlled trial of low-dose alpha-difluoromethylornithine in individuals at risk for colorectal cancer. Cancer Epidemiol Biomarkers Prev 7:989-992. (Pubitemid 28514098)
136. Ma, H., Li, X., Yang, Z., Okuno, S., Kawaguchi, T., Yagi, S., et al. (2011). High antimetastatic efficacy of MEN4901/T-0128, a novel camptothecin carboxymethyldextran conjugate. J Surg Res June 25 171:684-90.
137. Magrini, R., Bhonde, M. R., Hanski, M. L., Notter, M., Scherubl, H., Boland, C. R., et al. (2002). Cellular effects of CPT-11 on colon carcinoma cells: dependence on p53 and hMLH1 status. Int J Cancer 101:23-31. (Pubitemid 34832993)
138. Maier, T. J., Schilling, K., Schmidt, R., Geisslinger, G., Grosch, S. (2004). Cyclooxygenase-2 (COX-2)-dependent and-independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Biochem Pharmacol 67:1469-1478. (Pubitemid 38388209)
139. Marcus, P. M., Newcomb, P. A. (1998). The association of calcium and vitamin D, and colon and rectal cancer in Wisconsin women. Int J Epidemiol 27:788-793. (Pubitemid 28504965)
140. Marin, J. J., Romero, M. R., Martinez-Becerra, P., Herraez, E., Briz, O. (2009). Overview of the molecular bases of resistance to chemotherapy in liver and gastrointestinal tumours. Curr Mol Med 9:1108-1129.
141. Marsh, S., McKay, J. A., Cassidy, J., McLeod, H. L. (2001). Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int J Oncol 19:383-386.
142. Martinez, C., Garcia-Martin, E., Pizarro, R. M., Garcia-Gamito, F. J., Agundez, J. A. (2002). Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: implications for drug therapy. Br J Cancer 87:681-686.
143. Martinez, M. E., Giovannucci, E., Jiang, R., Henning, S. M., Jacobs, E. T., Thompson, P., et al. (2006). Folate fortification, plasma folate, homocysteine and colorectal adenoma recurrence. Int J Cancer 119:1440-1446. (Pubitemid 44258823)
144. Martinez, M. E., Henning, S. M., Alberts, D. S. (2004). Folate and colorectal neoplasia: relation between plasma and dietary markers of folate and adenoma recurrence. Am J Clin Nutr 79:691-697. (Pubitemid 41103916)
145. Martinez, M. E., Marshall, J. R., Giovannucci, E. (2008). Diet and cancer prevention: the roles of observation and experimentation. Nat Rev Cancer 8:694-703.
146. Martinez-Balibrea, E., Martinez-Cardus, A., Musulen, E., Gines, A., Manzano, J. L., Aranda, E., et al. (2009). Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin-based chemotherapy. Int J Cancer 124:2905-2910.
147. Mason, J. B., Dickstein, A., Jacques, P. F., Haggarty, P., Selhub, J., Dallal, G., et al. (2007). A temporal association between folic acid fortification and an increase in colorectal cancer rates may be illuminating important biological principles: a hypothesis. Cancer Epidemiol Biomarkers Prev 16:1325-1329. (Pubitemid 47076861)
148. McCullough, M. L., Robertson, A. S., Rodriguez, C., Jacobs, E. J., Chao, A., Carolyn, J., et al. (2003). Calcium, vitamin D, dairy products, and risk of colorectal cancer in the Cancer Prevention Study II Nutrition Cohort (United States). Cancer Causes Control 14: 1-12. (Pubitemid 36403263)
149. Meier, Y., Eloranta, J. J., Darimont, J., Ismair, M. G., Hiller, C., Fried, M., et al. (2007). Regional distribution of solute carrier mRNA expression along the human intestinal tract. Drug Metab Dispos 35:590-594. (Pubitemid 46513261)
150. Meijer, C., Timmer, A., De Vries, E. G., Groten, J. P., Knol, A., Zwart, N., et al. (2000). Role of metallothionein in cisplatin sensitivity of germ-cell tumours. Int J Cancer 85:777-781. (Pubitemid 30131464)
151. Merl, M., Hoimes, C., Pham, T., Saif, M. W. (2009). Is there a palliative benefit of gemcitabine plus fluoropyrimidines in patients with refractory colorectal cancer? A review of the literature previously presented: poster at the 2008 Gastrointestinal Cancer Symposium (Abstract No. 512). Expert Opin Investig Drugs 18:1257-1264.
152. Meyerhardt, J. A., Stuart, K., Fuchs, C. S., Zhu, A. X., Earle, C. C., Bhargava, P., et al. (2007). Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer. Ann Oncol 18:1185-1189. (Pubitemid 47244364)
153. Meyers, M., Wagner, M. W., Hwang, H. S., Kinsella, T. J., Boothman, D. A. (2001). Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine- mediated cell death and cell cycle responses. Cancer Res 61:5193-5201. (Pubitemid 32681553)
154. Meyskens, F. L., Jr., McLaren, C. E., Pelot, D., Fujikawa-Brooks, S., Carpenter, P. M., Hawk, E., et al. (2008). Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila) 1:32-38.
155. Mita, M. M., Ochoa, L., Rowinsky, E. K., Kuhn, J., Schwartz, G., Hammond, L. A., et al. (2006). A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer. Ann Oncol 17:313-321. (Pubitemid 43160123)
156. Moertel, C. G., Fleming, T. R., Macdonald, J. S., Haller, D. G., Laurie, J. A., Goodman, P. J., et al. (1990). Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322:352-358. (Pubitemid 20042739)
157. Mol, C. D., Dougan, D. R., Schneider, T. R., Skene, R. J., Kraus, M. L., Scheibe, D. N., et al. (2004). Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem 279:31655-31663. (Pubitemid 39037836)
158. Montagut, C., Iglesias, M., Arumi, M., Bellosillo, B., Gallen, M., Martinez-Fernandez, A., et al. (2010). Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to antiepidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients. Br J Cancer 102:1137-1144.
159. Nannizzi, S., Veal, G. J., Giovannetti, E., Mey, V., Ricciardi, S., Ottley, C. J., et al. (2010). Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines. Cancer Chemother Pharmacol 66: 547-558.
160. Negri, F. V., Bozzetti, C., Lagrasta, C. A., Crafa, P., Bonasoni, M. P., Camisa, R., et al. (2010). PTEN status in advanced colorectal cancer treated with cetuximab. Br J Cancer 102:162-164.
161. Nehls, O., Okech, T., Hsieh, C. J., Enzinger, T., Sarbia, M., Borchard, F., et al. (2007). Studies on p53, BAX and Bcl-2 protein expression and microsatellite instability in stage III (UICC) colon cancer treated by adjuvant chemotherapy: major prognostic impact of proapoptotic BAX. Br J Cancer 96:1409-1418. (Pubitemid 46685789)
162. Nielsen, O. H., Munck, L. K. (2007). Drug insight: aminosalicylates for the treatment of IBD. Nat Clin Pract Gastroenterol Hepatol 4:160-170. (Pubitemid 46416252)
163. Nunes, M., Shi, C., Greenberger, L. M. (2004). Phosphorylation of extracellular signal-regulated kinase 1 and 2, protein kinase B, and signal transducer and activator of transcription 3 are differently inhibited by an epidermal growth factor receptor inhibitor, EKB-569, in tumor cells and normal human keratinocytes. Mol Cancer Ther 3:21-27. (Pubitemid 39193675)
164. O'Connell, M. J., Laurie, J. A., Kahn, M., Fitzgibbons, R. J., Jr., Erlichman, C., Shepherd, L., et al. (1998). Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 16:295-300. (Pubitemid 28041612)
165. O'Neil, B. H., Allen, R., Spigel, D. R., Stinchcombe, T. E., Moore, D. T., Berlin, J. D., et al. (2007). High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol 25:3644-3648. (Pubitemid 47372602)
166. O'Neil, B. H., Tepper, J. E. (2007). Current options for the management of rectal cancer. Curr Treat Options Oncol 8:331-338.
167. Ocvirk, J., Brodowicz, T., Wrba, F., Ciuleanu, T. E., Kurteva, G., Beslija, S., et al. (2010). Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. World J Gastroenterol 16:3133-3143.
168. Okabe, M., Szakacs, G., Reimers, M. A., Suzuki, T., Hall, M. D., Abe, T., et al. (2008). Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters. Mol Cancer Ther 7:3081-3091.
169. Ouchi, K. F., Yanagisawa, M., Sekiguchi, F., Tanaka, Y. (2006). Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models. Cancer Chemother Pharmacol 57:693-702.
170. Pardi, D. S., Loftus, E. V., Jr., Kremers, W. K., Keach, J., Lindor, K. D. (2003). Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 124:889-893. (Pubitemid 36389790)
171. Park, Y., Hunter, D. J., Spiegelman, D., Bergkvist, L., Berrino, F., van den Brandt, P. A., et al. (2005). Dietary fiber intake and risk of colorectal cancer: a pooled analysis of prospective cohort studies. JAMA 294:2849-2857. (Pubitemid 41785865)
172. Pavillard, V., Agostini, C., Richard, S., Charasson, V., Montaudon, D., Robert, J. (2002). Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines. Cancer Chemother Pharmacol 49:329-335. (Pubitemid 34253272)
173. Pedersen, T. R., Berg, K., Cook, T. J., Faergeman, O., Haghfelt, T., Kjekshus, J., et al. (1996). Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med 156:2085-2092. (Pubitemid 26346967)
174. Peters, U., Sinha, R., Chatterjee, N., Subar, A. F., Ziegler, R. G., Kulldorff, M., et al. (2003). Dietary fibre and colorectal adenoma in a colorectal cancer early detection programme. Lancet 361:1491-1495. (Pubitemid 36566338)
175. Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., et al. (2007). Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28:622-629. (Pubitemid 46744292)
176. Pinedo, H. M., Peters, G. F. (1988). Fluorouracil: biochemistry and pharmacology. J Clin Oncol 6:1653-1664.
177. Pitts, T. M., Morrow, M., Kaufman, S. A., Tentler, J. J., Eckhardt, S. G. (2009). Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models. Mol Cancer Ther 8:342-349.
178. Plasencia, C., Martinez-Balibrea, E., Martinez-Cardus, A., Quinn, D. I., Abad, A., Neamati, N. (2006). Expression analysis of genes involved in oxaliplatin response and development of oxaliplatinresistant HT29 colon cancer cells. Int J Oncol 29:225-235.
179. Poincloux, L., Durando, X., Seitz, J. F., Thivat, E., Bardou, V. J., Giovannini, M. H., et al. (2009). Loss of Bcl-2 expression in colon cancer: a prognostic factor for recurrence in stage II colon cancer. Surg Oncol 18:357-365.
180. Poplin, E. A., Benedetti, J. K., Estes, N. C., Haller, D. G., Mayer, R. J., Goldberg, R. M., et al. (2005). Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer. J Clin Oncol 23:1819-1825. (Pubitemid 46211360)
181. Porschen, R., Arkenau, H. T., Kubicka, S., Greil, R., Seufferlein, T., Freier, W., et al. (2007). Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol 25:4217-4223. (Pubitemid 47548561)
182. Potocnik, U., Glavac, D., Dean, M. (2008). Common germline MDR1/ABCB1 functional polymorphisms and haplotypes modify susceptibility to colorectal cancers with high microsatellite instability. Cancer Genet Cytogenet 183:28-34. (Pubitemid 351636126)
183. Poynter, J. N., Gruber, S. B., Higgins, P. D., Almog, R., Bonner, J. D., Rennert, H. S., et al. (2005). Statins and the risk of colorectal cancer. N Engl J Med 352:2184-2192. (Pubitemid 40727085)
184. Raftery, L., Goldberg, R. M. (2010). Optimal delivery of cytotoxic chemotherapy for colon cancer. Cancer J 16:214-219.
185. Reardon, J. T., Vaisman, A., Chaney, S. G., Sancar, A. (1999). Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bisaceto-ammine- dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res 59:3968-3971. (Pubitemid 29393563)
186. Reid, M. E., Duffield-Lillico, A. J., Sunga, A., Fakih, M., Alberts, D. S., Marshall, J. R. (2006). Selenium supplementation and colorectal adenomas: an analysis of the nutritional prevention of cancer trial. Int J Cancer 118:1777-1781. (Pubitemid 43376443)
187. Reidy, D. L., Vakiani, E., Fakih, M. G., Saif, M. W., Hecht, J. R., Goodman-Davis, N., et al. (2010). Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab-or panitumumabrefractory metastatic colorectal cancer. J Clin Oncol 28:4240-4246.
188. Rial, N. S., Meyskens, F. L., Gerner, E. W. (2009). Polyamines as mediators of APC-dependent intestinal carcinogenesis and cancer chemoprevention. Essays Biochem 46:111-124.
189. Robertson, J. D., Botwood, N. A., Rothenberg, M. L., Schmoll, H. J. (2009). Phase III trial of FOLFOX plus bevacizumab or cediranib (AZD2171) as first-line treatment of patients with metastatic colorectal cancer: HORIZON III. Clin Colorectal Cancer 8:59-60.
190. Rothenberg, M. L., Eckardt, J. R., Kuhn, J. G., Burris, H. A., 3rd, Nelson, J., Hilsenbeck, S. G., et al. (1996). Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 14:1128-1135. (Pubitemid 26105519)
191. Rothenberg, M. L., LaFleur, B., Levy, D. E., Washington, M. K., Morgan-Meadows, S. L., Ramanathan, R K., et al. (2005). Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. J Clin Oncol 23:9265-9274.
192. Royal, R. E., Pingpank, J. F., Jr. (2008). Diagnosis and management of peritoneal carcinomatosis arising from adenocarcinoma of the colon and rectum. Semin Oncol 35:183-191. (Pubitemid 351479211)
193. Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., et al. (1996). The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335:1001-1009. (Pubitemid 26338729)
194. Salonga, D., Danenberg, K. D., Johnson, M., Metzger, R., Groshen, S., Tsao-Wei, D. D., et al. (2000). Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6:1322-1327. (Pubitemid 30226214)
195. Saltz, L. B., Clarke, S., Diaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., et al. (2008). Bevacizumab in combination with oxaliplatinbased chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013-2019.
196. Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., et al. (2000). Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905-914.
197. Saltz, L. B., Niedzwiecki, D., Hollis, D., Goldberg, R. M., Hantel, A., Thomas, J. P., et al. (2007). Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol 25:3456-3461. (Pubitemid 47310883)
198. Sanjoaquin, M. A., Allen, N., Couto, E., Roddam, A. W., Key, T. J. (2005). Folate intake and colorectal cancer risk: a meta-analytical approach. Int J Cancer 113:825-828. (Pubitemid 40101266)
199. Sartore-Bianchi, A., Martini, M., Molinari, F., Veronese, S., Nichelatti, M., Artale, S., et al. (2009). PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 69:1851-1857.
200. Sauer, R, Becker, H, Hohenberger, W, Rodel, C, Wittekind, C, Fietkau, R, et al. (2004). Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731-1740.
201. Saunders M. P., Wilson, R., Peeters, M., Smith, R., Godwood, A., Oliver, S., et al. (2009). Vandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: results from an openlabel, multicentre phase I study. Cancer Chemother Pharmacol 64: 665-672.
202. Schatzkin, A., Lanza, E., Corle, D., Lance, P., Iber, F., Caan, B., et al. (2000). Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. Polyp Prevention Trial Study Group. N Engl J Med 342:1149-1155. (Pubitemid 30211045)
203. Scheffer, G. L., Schroeijers, A. B., Izquierdo, M. A., Wiemer, E. A., Scheper, R. J. (2000). Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer. Curr Opin Oncol 12:550-556. (Pubitemid 32039654)
204. Schiffmann, S., Maier, T. J., Wobst, I., Janssen, A., Corban-Wilhelm, H., Angioni, C., et al. (2008). The anti-proliferative potency of celecoxib is not a class effect of coxibs. Biochem Pharmacol 76:179-187.
205. Schmoll, H. J., Cartwright, T., Tabernero, J., Nowacki, M. P., Figer, A., Maroun, J., et al. (2007). Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol 25:102-109. (Pubitemid 350003057)
206. Sengupta, S., Muir, J. G., Gibson, P. R. (2006). Does butyrate protect from colorectal cancer? J Gastroenterol Hepatol 21:209-218.
207. Shagisultanova, E. I., Piao, Z., Li, H. R., Malkhosyan, S. R. (2004). Topoisomerase II gene mutations in tumors and tumor cell lines with microsatellite instability. Cancer Lett 216:221-226. (Pubitemid 39463326)
208. Sharif, S., O'Connell, M. J., Yothers, G., Lopa, S., Wolmark, N. (2008). FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon cancer. Cancer Invest 26:956-963.
209. Shaukat, A., Scouras, N., Schunemann, H. J. (2005). Role of supplemental calcium in the recurrence of colorectal adenomas: a metaanalysis of randomized controlled trials. Am J Gastroenterol 100:390-394. (Pubitemid 40314524)
210. Siddiqui, A. D., Piperdi, B. (2010). KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy. Ann Surg Oncol 17:1168-1176.
211. Sigmond, J., Comijn, E. M., Kamphuis, J. A., Peters, G. J. (2004). Combinations of 5-fluorouracil with UCN-01 or staurosporine. Nucleosides Nucleotides Nucleic Acids 23:1503-1506. (Pubitemid 39625952)
212. Singer, C. F., Hudelist, G., Lamm, W., Mueller, R., Czerwenka, K., Kubista, E. (2004). Expression of tyrosine kinases in human malignancies as potential targets for kinase-specific inhibitors. Endocr Relat Cancer 11:861-869. (Pubitemid 40065558)
213. Sobrero, A. F., Maurel, J., Fehrenbacher, L., Scheithauer, W., Abubakr, Y. A., Lutz, M. P., et al. (2008). EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26:2311-2319.
214. Souglakos, J., Androulakis, N., Syrigos, K., Polyzos, A., Ziras, N., Athanasiadis, A., et al. (2006). FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer 94:798-805.
215. Spigel, D. R., Greco, F. A., Waterhouse, D., Shipley, D., Lane, C. M., Vazquez, E. R., et al. (2010). Phase II trial of FOLFOX6, bevacizumab, and cetuximab in the first-line treatment of metastatic colorectal cancer. Clin Adv Hematol Oncol 8:480-485.
216. Sturmer, T., Glynn, R. J., Lee, I. M., Manson, J. E., Buring, J. E., Hennekens, C. H. (1998). Aspirin use and colorectal cancer: posttrial follow-up data from the Physicians' Health Study. Ann Intern Med 128:713-720. (Pubitemid 28204862)
217. Sun, Y., Sun, J., Shi, S., Jing, Y., Yin, S., Chen, Y., et al. (2009). Synthesis, transport and pharmacokinetics of 5′-amino acid ester prodrugs of 1-beta-D-arabinofuranosylcytosine. Mol Pharm 6:315-325.
218. Taylor, P. R., Greenwald, P. (2005). Nutritional interventions in cancer prevention. J Clin Oncol 23:333-345. (Pubitemid 46209964)
219. Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M. M., Pastan, I., Willingham, M. C. (1987). Cellular localization of the multidrugresistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84:7735-7738.
220. Thompson, P. A., Wertheim, B. C., Zell, J. A., Chen, W. P., McLaren, C. E., LaFleur, B. J., et al. (2010). Levels of rectal mucosal polyamines and prostaglandin E2 predict ability of DFMO and sulindac to prevent colorectal adenoma. Gastroenterology 139:797-805.
221. Tournigand, C., Andre, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., et al. (2004). FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229-237. (Pubitemid 41095086)
222. Townsley, C. A., Major, P., Siu, L. L., Dancey, J., Chen, E., Pond, G. R., et al. (2006). Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. Br J Cancer 94:1136-1143.
223. Tung, B. Y., Emond, M. J., Haggitt, R. C., Bronner, M. P., Kimmey, M. B., Kowdley, K. V., et al. (2001). Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 134:89-95. (Pubitemid 32096335)
224. Twelves, C., Wong, A., Nowacki, M. P., Abt, M., Burris, H., 3rd, Carrato, A., et al. (2005). Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352:2696-2704. (Pubitemid 41007824)
225. Tyagi, P. (2005). Vatalanib (PTK787/ZK 222584) in combination with FOLFOX4 versus FOLFOX4 alone as first-line treatment for colorectal cancer: preliminary results from the CONFIRM-1 trial. Clin Colorectal Cancer 5:24-26.
226. Tytherleigh, M. G., Warren, B. F., Mortensen, N. J. (2008). Management of early rectal cancer. Br J Surg 95:409-423.
227. Van Cutsem, E., Dicato, M., Haustermans, K., Arber, N., Bosset, J. F., Cunningham, D., et al. (2008). The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007. Ann Oncol 19:vi1-8.
228. Van Cutsem, E., Kohne, C. H., Hitre, E., Zaluski, J., Chang Chien, C. R., Makhson, A., et al. (2009a). Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408-1417.
229. Van Cutsem, E., Labianca, R., Bodoky, G., Barone, C., Aranda, E., Nordlinger, B., et al. (2009b). Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 27:3117-3125.
230. Van Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., et al. (2007). Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol, 25, 1658-64. (Pubitemid 46797944)
231. Van Cutsem, E., Twelves, C., Cassidy, J., Allman, D., Bajetta, E., Boyer, M., et al. (2001). Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19:4097-4106. (Pubitemid 33049527)
232. Veronese, M. L., Sun, W., Giantonio, B., Berlin, J., Shults, J., Davis, L., et al. (2005). A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer. Br J Cancer 92:1846-1849. (Pubitemid 40826131)
233. Vincenzi, B., Santini, D., Rabitti, C., Coppola, R., Beomonte Zobel, B., Trodella, L., et al. (2006). Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial. Br J Cancer 94:792-797.
234. Wactawski-Wende, J., Kotchen, J. M., Anderson, G. L., Assaf, A. R., Brunner, R. L., O'Sullivan, M. J., et al. (2006). Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 354:684-696. (Pubitemid 43247139)
235. Wang, W., McLeod, H. L., Cassidy, J., Collie-Duguid, E. S. (2007). Mechanisms of acquired chemoresistance to 5-fluorouracil and tomudex: thymidylate synthase dependent and independent networks. Cancer Chemother Pharmacol 59:839-845. (Pubitemid 46440607)
236. Webley, S. D., Welsh, S. J., Jackman, A. L., Aherne, G. W. (2001). The ability to accumulate deoxyuridine triphosphate and cellular response to thymidylate synthase (TS) inhibition. Br J Cancer 85:446-452. (Pubitemid 32747716)
237. West, N. P., Hohenberger, W., Weber, K., Perrakis, A., Finan, P. J., Quirke, P. (2010). Complete mesocolic excision with central vascular ligation produces an oncologically superior specimen compared with standard surgery for carcinoma of the colon. J Clin Oncol 28:272-278.
238. Wolmark, N., Rockette, H., Mamounas, E., Jones, J., Wieand, S., Wickerham, D. L., et al. (1999). Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 17:3553-3559. (Pubitemid 29517927)
239. Wolmark, N., Wieand, S., Kuebler, J., Colangelo, L., O'Connell, M. J., Yothers, G. (2008). A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Survival results of NSABP Protocol C-07. J Clin Oncol 26:1008S.
240. Wood, J. M., Bold, G., Buchdunger, E., Cozens, R., Ferrari, S., Frei, J., et al. (2000). PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60:2178-2189. (Pubitemid 30225181)
241. Xu, Y., Fang, F., Ludewig, G., Jones, G., Jones, D. (2004). A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. DNA Cell Biol 23:419-429. (Pubitemid 38981976)
242. Yan, T. D., Black, D., Savady, R., Sugarbaker, P. H. (2006). Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol 24:4011-4019. (Pubitemid 46630752)
243. Ychou, M., Raoul, J. L., Douillard, J. Y., Gourgou-Bourgade, S., Bugat, R., Mineur, L., et al. (2009). A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol 20:674-680.
244. Yonezawa, A., Masuda, S., Yokoo, S., Katsura, T., Inui, K. (2006). Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther 319:879-886.